布仑妥昔单抗维多汀
医学
内科学
耐火材料(行星科学)
肿瘤科
完全缓解
淋巴瘤
霍奇金淋巴瘤
化疗
胃肠病学
外科
生物
天体生物学
作者
Robert Chen,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dirk Huebner,Abraham Fong,Anas Younes
出处
期刊:Blood
[American Society of Hematology]
日期:2016-09-22
卷期号:128 (12): 1562-1566
被引量:311
标识
DOI:10.1182/blood-2016-02-699850
摘要
Key Points A total of 38% of patients who achieved CR (13 of 34) on brentuximab vedotin have remained in remission for >5 years and may be cured. Nine of the 13 patients (9% of all enrolled patients) have remained in long-term remission without a consolidative allogeneic transplant.
科研通智能强力驱动
Strongly Powered by AbleSci AI